Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Non-Current Assets (2022 - 2026)

Compass Therapeutics' Non-Current Assets history spans 5 years, with the latest figure at $9.5 million for Q1 2026.

  • On a quarterly basis, Non-Current Assets rose 29.8% to $9.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was $39.9 million, a 59.36% increase, with the full-year FY2025 number at $9.8 million, up 27.67% from a year prior.
  • Non-Current Assets hit $9.5 million in Q1 2026 for Compass Therapeutics, down from $9.8 million in the prior quarter.
  • Over the last five years, Non-Current Assets for CMPX hit a ceiling of $10.5 million in Q2 2025 and a floor of $2.1 million in Q2 2024.
  • Historically, Non-Current Assets has averaged $6.2 million across 5 years, with a median of $6.1 million in 2022.
  • Biggest five-year swings in Non-Current Assets: plummeted 47.17% in 2024 and later skyrocketed 408.62% in 2025.
  • Tracing CMPX's Non-Current Assets over 5 years: stood at $4.9 million in 2022, then crashed by 38.32% to $3.0 million in 2023, then skyrocketed by 155.58% to $7.7 million in 2024, then increased by 27.67% to $9.8 million in 2025, then dropped by 2.93% to $9.5 million in 2026.
  • Business Quant data shows Non-Current Assets for CMPX at $9.5 million in Q1 2026, $9.8 million in Q4 2025, and $10.1 million in Q3 2025.